Last reviewed · How we verify
NCT07272603
Bladder Perfusion of Plasma-Activated Saline for Bladder Cancer
EARLY_PHASE1 trial testing Plasma-Activated Saline Solution (PASS) Bladder Instillation in Bladder (Urothelial, Transitional Cell) Cancer in 5 participants. Not yet recruiting.
15 February 2026
Quick facts
| Lead sponsor | Qilu Hospital of Shandong University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 15 December 2025 |
| Primary completion | 15 February 2026 |
| Estimated completion | 15 February 2026 |
Drugs / interventions tested
- Plasma-Activated Saline Solution (PASS) Bladder Instillation — full drug profile →
Conditions studied
- Bladder (Urothelial, Transitional Cell) Cancer — all drugs for Bladder (Urothelial, Transitional Cell) Cancer →
Sponsor
Qilu Hospital of Shandong University
Who can join
Adults 18 to 75, any sex, with Bladder (Urothelial, Transitional Cell) Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This preliminary clinical study evaluates the safety and initial efficacy of a novel therapy called Plasma-Activated Saline Solution (PASS) for bladder cancer patients. The study involves a one-week course of PASS administered via bladder infusion in five pre-surgical patients, using imaging and pathology analyses to assess tumor shrinkage and cancer cell death, while closely monitoring for any adverse reactions to explore the therapy's future potential.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07272603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder (Urothelial, Transitional Cell) Cancer
Currently open trials in the same condition.
- NCT07589413 — Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT · recruiting
- NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
- NCT06787053 — Selecting Hypoxic Tumours for Treatment Modification · recruiting
- NCT06696742 — PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma · Phase 2 · recruiting
Other Qilu Hospital of Shandong University trials
Trials by the same sponsor.
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
- NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
- NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
- NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
- NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07272603 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07272603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing